drugset
drugset / Trial / NCT04444466

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

NCT04444466 ↗

Phase 1 Terminated 40 enrolled UCB Biopharma SRL
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of the study is to assess safety, tolerability and pharmacokinetics (PK) of oral UCB8600.

Timeline

Start
2020-06-30
Primary completion
2021-08-02
Completion
2021-08-02

Outcome

Outcome not reported

Stopped: “internal company decision; not safety related”

Drugs

EvaluationDrugModalityDoseRoute
Subject UCB8600 Unknown — Oral

Indications

chronic urticaria